DOCSLIB.ORG

Therapeutics of Vitamin D

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutics of Vitamin D 5 179 P R Ebeling and others Vitamin D 179:5 R239–R259 Review MANAGEMENT OF ENDOCRINE DISEASE Therapeutics of vitamin D P R Ebeling1, R A Adler2, G Jones3, U A Liberman4, G Mazziotti5, S Minisola6, C F Munns7, N Napoli8,13, A G Pittas9, A Giustina10, J P Bilezikian11 and R Rizzoli12 1Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia, 2McGuire Veterans Affairs Medical Center and Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA, 3Department of Biomedical and Molecular Sciences in the School of Medicine, Queen’s University, Kingston, Ontario, Canada, 4Department of Physiology and Pharmacology and The Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, 5Endocrine Unit, ASST Carlo Poma, Mantua, Italy, 6‘Sapienza’ Rome University, Rome, Italy, 7Department of Paediatrics, Westmead Children’s Hospital, The University of Sydney, Westmead, New South Wales, Australia, 8Unit of Endocrinology and Diabetes, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy, 9Division of Endocrinology, Tufts Medical Center, Boston, Massachusetts, USA, 10Vita-Salute, San Raffaele University, Milan, Italy, 11Division of Correspondence Endocrinology, College of Physicians & Surgeons, Columbia University, New York, New York, USA, 12Divison of Bone should be addressed Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, 13IRCCS, Istituto Ortopedico to P R Ebeling Galeazzi, Milan, Italy Email peter.ebeling@monash.edu Abstract Objective: The central role of vitamin D in bone health is well recognized. However, controversies regarding its clinical application remain. We therefore aimed to review the definition of hypovitaminosis D, the skeletal and extra-skeletal effects of vitamin D and the available therapeutic modalities. Design: Narrative and systematic literature review. Methods: An international working group that reviewed the current evidence linking bone and extra-skeletal health and vitamin D therapy to identify knowledge gaps for future research. Results: Findings from observational studies and randomized controlled trials (RCTs) in vitamin D deficiency are discordant, with findings of RCTs being largely negative. This may be due to reverse causality with the illness itself European Journal European of Endocrinology contributing to low vitamin D levels. The results of many RCTs have also been inconsistent. However, overall evidence from RCTs shows vitamin D reduces fractures (when administered with calcium) in the institutionalized elderly. Although controversial, vitamin D reduces acute respiratory tract infections (if not given as bolus monthly or annual doses) and may reduce falls in those with the lowest serum 25-hydroxyvitamin D (25OHD) levels. However, despite large ongoing RCTs with 21 000–26 000 participants not recruiting based on baseline 25OHD levels, they will contain a large subset of participants with vitamin D deficiency and are adequately powered to meet their primary end-points. Conclusions: The effects of long-term vitamin D supplementation on non-skeletal outcomes, such as type 2 diabetes mellitus (T2DM), cancer and cardiovascular disease (CVD) and the optimal dose and serum 25OHD level that balances extra-skeletal benefits (T2DM) vs risks (e.g. CVD), may soon be determined by data from large RCTs. European Journal of Endocrinology (2018) 179, R239–R259 Introduction The central role of vitamin D in bone health is well skeletal effects of vitamin D and the different therapeutic recognized. However, a series of controversies regarding modalities available. To identify the controversial issues, its clinical application remain. They primarily concern summarize the present state of knowledge and formulate how to define hypovitaminosis D, the skeletal and extra- some research questions to answer these controversies, https://eje.bioscientifica.com © 2018 European Society of Endocrinology Published by Bioscientifica Ltd. https://doi.org/10.1530/EJE-18-0151 Printed in Great Britain Downloaded from Bioscientifica.com at 09/30/2021 10:50:24PM via free access -18-0151 Review P R Ebeling and others Vitamin D 179:5 R240 a meeting was held in June 2017, during which the such as in Scandanavian countries, the use of cod liver various aspects of vitamin D measurement, its effects and oil and food fortification with vitamin D leads to higher therapeutic applications were reviewed and discussed by levels of 25-hydroxyvitamin D than would be expected international experts in the field. In this paper, we address (5, 6). Methods to increase vitamin D intake across a these issues. given population, including bio-fortification consisting of adding vitamin D to livestock feeds or UVB-irradiation of mushrooms and baker’s yeast are under evaluation (7, 8). Methods For the treatment of hypovitaminosis D, either sun exposure or increased intake of vitamin D-fortified This commentary reflects the discussion of a working foods may not be sufficient. In these settings, vitamin group that reviewed the current evidence linking bone D supplements should be considered, with various health and vitamin D therapy. It is based on both narrative guidelines suggesting either vitamin D2 (ergocalciferol) or and systematic literature reviews, focusing on the most vitamin D3 (cholecalciferol) (9). Vitamin D3 seems to be robust clinical evidence, which constituted the search preferred by many experts because of its greater potency criteria in PubMed. (10, 11). Interestingly, a meta-analysis of double-blind RCTs Vitamin D as a therapeutic agent and document that focused on a dose of vitamin D >480 IU/ its administration day the pooled effect of vitamin D3 on fractures was significantly lower by 23%, while the pooled effect on Questions relating to areas of agreement: fractures was not significant with vitamin 2D (12). When vitamin D and D are considered together, a Cochrane • Is vitamin D3 superior to D2? – Pharmacokinetics, 2 3 clinical data. analysis showed a significant decrease in incidence of hip • What is the role for 25-hydroxyvitamin D in fractures and non-vertebral fractures in patients treated replacement and its availability? with vitamin D plus calcium vs no treatment (13). • Is there a place for active vitamin D metabolites in Regarding vitamin D metabolites in cases of age- or treating vitamin deficiency? disease-related declines in hepatic and renal function • Is daily dosing of vitamin D preferred to larger weekly, (14), 25-hydroxyvitamin D (calcidiol) can be used, when monthly or annual doses? available. However, calcidiol is not available in the United • Does the baseline level of serum 25-hydroxyvitamin D States. In patients with advanced liver disease in whom European Journal European of Endocrinology influence the choice and frequency of dose? the hepatic hydroxylation of vitamin D is impaired, • Does BMI or race influence the dose or mode of calcidiol would be a logical form because it bypasses that administration? hydroxylation step in the liver (14). It is also a logical • What is the role of fortification in increasing vitamin form of vitamin D to use in the setting of glucocorticoid- D? induced inhibition of hepatic 25-hydroxylase. (15). • How much is too much vitamin D? Since glucocorticoids may inhibit not only the hepatic • What adverse outcomes are important? 25-hydroxylation of vitamin D, but also the subsequent 1-hydroxylation step in the kidney, to form active calcitriol, the use of calcitriol has been proposed as a way Type and source of vitamin D: metabolites, active forms of bypassing both hydroxylation steps for the treatment and analogues of glucocorticoid-induced osteoporosis (GIOP). Indeed, Skin is the major source of cholecalciferol in humans, in some clinical studies, active vitamin D analogues which is formed after exposure to the ultraviolet B were shown to be more effective than native vitamin D3 (UVB) wavelength of sunlight. A number of personal in terms of bone mineral density (BMD) improvement and environmental factors reduce the skin production and reduction of fracture risk in GIOP (16). However, in of vitamin D, such as low UVB availability, which is other studies of GIOP, the effects of native vitamin D3 dependent, in part, on latitude, season, time of day were comparable with those achieved by active vitamin and extent of air pollution (1, 2, 3). Even so, in regions D analogues (17). Moreover, calcidiol has been proposed of high UVB availability, a substantial prevalence of for the treatment of hypovitaminosis D in obese patients hypovitaminosis D has been reported (4). On the other due to its greater hydrophilic properties, in comparison hand, in countries where UVB availability is generally low, with vitamin D itself, resulting in a smaller volume of https://eje.bioscientifica.com Downloaded from Bioscientifica.com at 09/30/2021 10:50:24PM via free access Review P R Ebeling and others Vitamin D 179:5 R241 distribution and potentially more rapid and effective prevalence of vitamin D deficiency in older individuals, a normalization of serum 25-hydroxyvitamin D values daily intake of 600–800 IU is recommended (21). At both (14). Calcidiol may also be the most preferred form of ends of the life span, an adequate intake of calcium is vitamin D in cases of fat malabsorption due to a variety also necessary. of diseases or following bariatric surgery (14). This discussion of advantages of calcidiol over vitamin D itself Mode of administration and
Load more

Recommended publications
  • Extended-Release 30 Mcg Capsules Service Request Form Fax: 1-844-660-7083 | Phone: 1-844-414-Opko (6756) E-Mail: Opkoconnect@Rxallcare.Com
    RAYALDEE® (CALCIFEDIOL) EXTENDED-RELEASE 30 MCG CAPSULES SERVICE REQUEST FORM FAX: 1-844-660-7083 | PHONE: 1-844-414-OPKO (6756) E-MAIL: OPKOCONNECT@RXALLCARE.COM 1. Patient Information Please complete all fields to prevent any delays. New start to Rayaldee® therapy Existing patient on therapy E-mail Address: Preferred Method of Contact: Cell Phone Home Phone Email Text First Name Last Name SS # (Last 4 only) Preferred Time of Contact: Morning Afternoon Evening Male Female Ok to leave a message: Yes No Date of Birth (MM/DD/YYYY) Primary Language: English Spanish Other:________________________________ 2. Patient Insurance Information Address Attached is a copy of both sides of the patient's insurance card City State ZIP Primary Insurance Phone # Cell Phone Home Phone Policy Holder Name Relationship to Patient Alternate Contact or Healthcare Proxy First Name, Last Name and Phone Insurance ID # Group # 3. Patient Clinical Information Please include supporting clinical documentation. ● ICD-10 Code: ● Lab Values & dates: Please check box 1. or 2. below 25(OH)D__________|__________ Calcium__________|__________ (N18.3) CKD stage 3, (N25.81) Secondary hyperparathyroidism, and 1. value date value date (E55.9) Vitamin D deficiency 2. (N18.4) CKD stage 4, (N25.81) Secondary hyperparathyroidism, and (E55.9) Vitamin D deficiency ● Therapies within the previous 6 months: No previous therapies Hectorol® (doxercalciferol) Rocaltrol® (calcitriol) OTC Vitamin D2 ® OTC Vitamin D3 Prescription Vitamin D2 (ergocalciferol) Zemplar (paricalcitol) 4. Prescriber Information Specialty of Prescriber: Nephrologist PCP Endocrinologist Internist First Name Last Name Phone Fax Practice Name Oce Contact Preferred Time of Contact Address NPI # City State ZIP 5.
    [Show full text]
  • A Left/Right Comparison of Twice-Daily Calcipotriol Ointment and Calcitriol Ointment in Patients with Psoriasis: the Effect on Keratinocyte Subpopulations
    Acta Derm Venereol 2004; 84: 195–200 INVESTIGATIVE REPORT A Left/Right Comparison of Twice-Daily Calcipotriol Ointment and Calcitriol Ointment in Patients with Psoriasis: The Effect on Keratinocyte Subpopulations Mannon E.J. FRANSSEN, Gys J. DE JONGH, Piet E.J. VAN ERP and Peter C.M. VAN DE KERKHOF Department of Dermatology, University Medical Centre Nijmegen, The Netherlands Vitamin D3 analogues are a first-line treatment of Calcipotriol (Daivonex1,50mg/g ointment, Leo chronic plaque psoriasis, but so far, comparative clinical Pharmaceutical Products, Denmark) has been investi- studies on calcipotriol and calcitriol ointment are sparse, gated intensively during the last decade, and has proven and in particular no comparative studies are available on to be a valuable tool in the management of chronic cell biological effects of these compounds in vivo. Using plaque psoriasis. A review by Ashcroft et al. (1), based on flow cytometric assessment, we investigated whether these a large number of randomized controlled trials, showed compounds had different effects on the composition and that calcipotriol was at least as effective as potent DNA synthesis of epidermal cell populations responsible topical corticosteroids, 1a,-25-dihydroxycholecalciferol for the psoriatic phenotype. For 8 weeks, 20 patients with (calcitriol), short-contact dithranol, tacalcitol and coal psoriasis vulgaris were treated twice daily with calcipo- tar. Recently, Scott et al. (2) presented an overview of triol and calcitriol ointment in a left/right comparative studies on the use of calcipotriol ointment in the study. Before and after treatment, clinical assessment of management of psoriasis. They reconfirmed the super- target lesions was performed, together with flow cyto- ior efficacy of a twice-daily calcipotriol ointment metric analysis of epidermal subpopulations with respect regimen to the treatments as mentioned above, and to keratin (K) 10, K6, vimentin and DNA distribution.
    [Show full text]
  • Endocrine System WS19
    Endocrine System Human Physiology Unit 3 Endocrine System • Various glands located throughout the body • Some organs may also have endocrine functions • Endocrine glands/organs synthesize and release hormones • Hormones travel in plasma to target cells Functions of the Endocrine System • Differentiation of nervous and reproductive system during fetal development • Regulation of growth and development • Regulation of the reproductive system • Maintains homeostasis • Responds to changes from resting state Mechanisms of Hormone Regulation • Hormones have different rates and rhythms of secretion • Hormones are regulated by feedback systems to maintain homeostasis • Receptors for hormones are only on specific effector cells • Excretion of hormones vary for steroid hormones and peptide hormones Regulation of Hormone Secretion • Release of hormones occurs in response to • A change from resting conditions • Maintaining a regulated level of hormones or substances • Hormone release is regulated by • Chemical factors (glucose, calcium) • Endocrine factors (tropic hormones, HPA) HPA = Hypothalamic-Pituitary Axis • Neural controls (sympathetic activation) Hormone Feedback Systems Negative feedback maintains hormone concentrations within physiological ranges • Negative feedback • Feedback to one level Loss of • Long-loop Negative Feedback feedback • Feedback to two levels control often leads to • Hypothalamus-Pituitary-Gland Axis pathology Negative Feedback Short-Loop Negative Feedback Long-Loop Negative Feedback Hormone Transport Peptide/Protein Hormones
    [Show full text]
  • Daily Lifestyle Modifications to Improve Quality of Life And
    brain sciences Review Daily Lifestyle Modifications to Improve Quality of Life and Survival in Glioblastoma: A Review Sarah Travers and N. Scott Litofsky * Division of Neurosurgery, University of Missouri School of Medicine, Columbia, MO 65212, USA; traverss@health.missouri.edu * Correspondence: litofskyn@health.missouri.edu Abstract: Survival in glioblastoma remains poor despite advancements in standard-of-care treatment. Some patients wish to take a more active role in their cancer treatment by adopting daily lifestyle changes to improve their quality of life or overall survival. We review the available literature through PubMed and Google Scholar to identify laboratory animal studies, human studies, and ongoing clinical trials. We discuss which health habits patients adopt and which have the most promise in glioblastoma. While results of clinical trials available on these topics are limited, dietary restrictions, exercise, use of supplements and cannabis, and smoking cessation all show some benefit in the comprehensive treatment of glioblastoma. Marital status also has an impact on survival. Further clinical trials combining standard treatments with lifestyle modifications are necessary to quantify their survival advantages. Keywords: survival in glioblastoma; dietary restriction in glioblastoma; cannabis use in glioblastoma; supplementation in glioblastoma; glioblastoma health modifications Citation: Travers, S.; Litofsky, N.S. Daily Lifestyle Modifications to 1. Introduction Improve Quality of Life and Survival Glioblastoma remains the most aggressive and deadly form of primary brain tumor, in Glioblastoma: A Review. Brain Sci. with average survival rates ranging from 7.8 to 23.4 months after diagnosis [1]. Maximal 2021, 11, 533. https://doi.org/ surgical resection followed by radiation and temozolomide have become standard of 10.3390/brainsci11050533 care [2,3].
    [Show full text]
  • The Role of Reproductive Hormones in Epithelial Ovarian Carcinogenesis
    H Gharwan et al. Hormones and epithelial 22:6 R339–R363 Review ovarian cancer The role of reproductive hormones in epithelial ovarian carcinogenesis Helen Gharwan1, Kristen P Bunch2,3 and Christina M Annunziata2 1National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, 12N226, Bethesda, Correspondence Maryland 20892-1906, USA should be addressed 2Women’s Malignancies Branch, National Cancer Institute, National Institutes of Health, Center for Cancer Research, to H Gharwan Bethesda, Maryland, USA Email 3Department of Gynecologic Oncology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA hgh7@hotmail.com Abstract Epithelial ovarian cancer comprises w85% of all ovarian cancer cases. Despite acceptance Key Words regarding the influence of reproductive hormones on ovarian cancer risk and considerable " ovarian cancer advances in the understanding of epithelial ovarian carcinogenesis on a molecular level, " hormone action complete understanding of the biologic processes underlying malignant transformation of " reproductive ovarian surface epithelium is lacking. Various hypotheses have been proposed over the past " immune several decades to explain the etiology of the disease. The role of reproductive hormones in " endocrine epithelial ovarian carcinogenesis remains a key topic of research. Primary questions in the field of ovarian cancer biology center on its developmental cell of origin, the positive and negative effects of each class of hormones on ovarian cancer initiation and progression, and the role of the immune system in the ovarian cancer microenvironment. The development of the female reproductive tract is dictated by the hormonal milieu during embryogenesis. Endocrine-Related Cancer Intensive research efforts have revealed that ovarian cancer is a heterogenous disease that may develop from multiple extra-ovarian tissues, including both Mu¨ llerian (fallopian tubes, endometrium) and non-Mu¨ llerian structures (gastrointestinal tissue), contributing to its heterogeneity and distinct histologic subtypes.
    [Show full text]
  • Acne Vulgaris and Intake of Selected Dietary Nutrients—A Summary of Information
    healthcare Review Acne Vulgaris and Intake of Selected Dietary Nutrients—A Summary of Information Aleksandra Podgórska †, Anna Pu´scion-Jakubik*,† , Renata Markiewicz-Zukowska˙ , Krystyna Joanna Gromkowska-K˛epkaand Katarzyna Socha Department of Bromatology, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, Mickiewicza 2D Street, 15-222 Białystok, Poland; apodgorska1@student.umb.edu.pl (A.P.); renmar@poczta.onet.pl (R.M.-Z.);˙ krystyna.gromkowska.kepka@gmail.com (K.J.G.-K.); katarzyna.socha@umb.edu.pl (K.S.) * Correspondence: anna.puscion-jakubik@umb.edu.pl; Tel.: +48-8574-854-69 † Contributed equally. Abstract: Acne vulgaris (AV) is a chronic disease that affects a significant percentage of the world’s population. Its development is influenced by both external and internal factors. The purpose of this review is to demonstrate the effect of basic nutrient intake on the exacerbation or alleviation of AV lesions. A retrospective review of publications in PubMed regarding diet therapy and the impact of individual nutrient intake on the skin condition of patients was conducted. Ingestion of products with a high glycaemic index may indirectly lead to sebum overproduction, which promotes infection with Cutibacterium acnes and causes inflammation. Consumption of certain dairy products may result Citation: Podgórska, A.; in skin deterioration caused by the presence of hormones in these products, i.e., progesterone and Pu´scion-Jakubik,A.; testosterone precursors. The beneficial effect of fatty acids on the skin is manifested by the reduction Markiewicz-Zukowska,˙ R.; Gromkowska-K˛epka,K.J.; Socha, K. in inflammation. Of significance in AV treatment are vitamins A, C, D, E and B, as well as mineral Acne Vulgaris and Intake of Selected elements zinc and selenium.
    [Show full text]
  • Controversies in Vitamin D: Summary Statement from an International Conference
    REPORTS AND RECOMMENDATIONS Controversies in Vitamin D: Summary Statement From an International Conference Andrea Giustina,1 Robert A. Adler,2 Neil Binkley,3 Roger Bouillon,4 Peter R. Ebeling,5 Marise Lazaretti-Castro,6 Claudio Marcocci,7 Rene Rizzoli,8 Christopher T. Sempos,9 and John P. Bilezikian10 1Endocrinology and Metabolism, Vita-Salute San Raffaele University, 20122 Milano Italy; 2McGuire Veterans Downloaded from https://academic.oup.com/jcem/article/104/2/234/5148139 by guest on 27 September 2021 Affairs Medical Center and Virginia Commonwealth University School of Medicine, Richmond, Virginia 23249; 3Osteoporosis Clinical Research Program and Institute on Aging, University of Wisconsin-Madison, Madison, Wisconsin 53705; 4Department of Chronic Diseases, Metabolism and Ageing, Laboratory of Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven 3000, Belgium; 5Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria 3168, Australia; 6Division of Endocrinology, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, 05437-000 Sao Paulo, Brazil; 7Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy; 8Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, 1211 Geneva 14 Geneva, Switzerland; 9Department of Population Health Sciences, University of Wisconsin-Madison, Madison, Wisconsin 21078; and 10Endocrinology Division, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032 ORCiD numbers: 0000-0002-1570-2617 (J. P. Bilezikian). Context: Vitamin D is classically recognized as a regulator of calcium and phosphorus metabolism. Recent advances in the measurement of vitamin D metabolites, diagnosis of vitamin D deficiency, and clinical observations have led to an appreciation that along with its role in skeletal metabolism, vitamin D may well have an important role in nonclassical settings.
    [Show full text]
  • (SBEM) for the Diagnosis and Treatment of Hypovitaminosis D
    consenso Recomendações da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) para o diagnóstico e tratamento da hipovitaminose D Recommendations of the Brazilian Society of Endocrinology and Metabology (SBEM) for the diagnosis and treatment of hypovitaminosis D Sergio Setsuo Maeda1, Victoria Z. C. Borba2, Marília Brasilio Rodrigues Camargo1, Dalisbor Marcelo Weber Silva3, João Lindolfo Cunha Borges4, Francisco Bandeira5, Marise Lazaretti-Castro1 RESUMO Objetivo: Apresentar uma atualização sobre o diagnóstico e tratamento da hipovitaminose 1 Disciplina de Endocrinologia, D baseada nas mais recentes evidências científicas.Materiais e métodos: O Departamento Universidade Federal de São de Metabolismo Ósseo e Mineral da Sociedade Brasileira de Endocrinologia e Metabologia Paulo, Escola Paulista de Medicina (Unifesp/EPM), São Paulo, SP, Brasil (SBEM) foi convidado a conceber um documento seguindo as normas do Programa Diretrizes 2 Departamento de Clínica Médica, da Associação Médica Brasileira (AMB). A busca dos dados foi realizada por meio do PubMed, Universidade Federal do Paraná Lilacs e SciELO e foi feita uma classificação das evidências em níveis de recomendação, de (UFPR), Curitiba, PR, Brasil 3 Departamento de Clínica acordo com a força científica por tipo de estudo. Conclusão: Foi apresentada uma atualização Médica, Faculdade de Medicina científica a respeito da hipovitaminose D que servirá de base para o diagnóstico e tratamento da Univille, Joinville, SC, Brasil 4 dessa condição no Brasil. Arq Bras Endocrinol Metab. 2014;58(5):411-33 Disciplina de Endocrinologia, Universidade Católica de Brasília Descritores (UCB), Brasília, DF, Brasil 5 Vitamina D; colecalciferol; PTH; osteoporose; deficiência; insuficiência; diagnóstico; tratamento Disciplina de Endocrinologia, Hospital Agamenon Magalhães, Universidade de Pernambuco ABSTRACT (UPE), Escola de Medicina, Recife, PE, Brasil Objective: The objective is to present an update on the diagnosis and treatment of hypovita­ minosis D, based on the most recent scientific evidence.
    [Show full text]
  • Vitamin D and Its Analogues Decrease Amyloid- (A) Formation
    International Journal of Molecular Sciences Article Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation Marcus O. W. Grimm 1,2,3,*,† ID , Andrea Thiel 1,† ID , Anna A. Lauer 1 ID , Jakob Winkler 1, Johannes Lehmann 1,4, Liesa Regner 1, Christopher Nelke 1, Daniel Janitschke 1,Céline Benoist 1, Olga Streidenberger 1, Hannah Stötzel 1, Kristina Endres 5, Christian Herr 6 ID , Christoph Beisswenger 6, Heike S. Grimm 1 ID , Robert Bals 6, Frank Lammert 4 and Tobias Hartmann 1,2,3 1 Experimental Neurology, Saarland University, Kirrberger Str. 1, 66421 Homburg/Saar, Germany; andrea.thiel@uks.eu (A.T.); Anna.Lauer@uks.eu (A.A.L.); jakob.winkler@uks.eu (J.W.); Johannes.Lehmann@uks.eu (J.L.); liesa.regner@uks.eu (L.R.); s8chnelk@stud.uni-saarland.de (C.N.); Daniel.janitschke@uks.eu (D.J.); s8cebeno@stud.uni-saarland.de (C.B.); olga.streidenberger@uks.eu (O.S.); hannah.stoetzel@uks.eu (H.S.); heike.grimm@uks.eu (H.S.G.); tobias.hartmann@uniklinikum-saarland.de (T.H.) 2 Neurodegeneration and Neurobiology, Saarland University, Kirrberger Str. 1, 66421 Homburg/Saar, Germany 3 Deutsches Institut für DemenzPrävention (DIDP), Saarland University, Kirrberger Str. 1, 66421 Homburg/Saar, Germany 4 Department of Internal Medicine II–Gastroenterology, Saarland University Hospital, Saarland University, Kirrberger Str. 100, 66421 Homburg/Saar, Germany; frank.lammert@uks.eu 5 Department of Psychiatry and Psychotherapy, Clinical Research Group, University Medical Centre Johannes Gutenberg, University of Mainz, Untere Zahlbacher Str. 8, 55131 Mainz, Germany; kristina.endres@unimedizin-mainz.de 6 Department of Internal Medicine V–Pulmonology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital, Kirrberger Str.
    [Show full text]
  • Eldecalcitol Is More Effective for Promoting Osteogenesis Than Alfacalcidol in Cyp27b1-Knockout Mice
    bioRxiv preprint doi: https://doi.org/10.1101/349837; this version posted June 18, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Eldecalcitol is more effective for promoting osteogenesis than alfacalcidol in Cyp27b1-knockout Mice Short title: Osteogenic effect of eldecalcitol Yoshihisa Hirota1,2*¶, Kimie Nakagawa2¶, Keigo Isomoto2¶, Toshiyuki Sakaki3, Noboru Kubodera4, Maya Kamao2, Naomi Osakabe5, Yoshitomo Suhara6, Toshio Okano2* 1 Laboratory of Biochemistry, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan 2 Laboratory of Hygienic Sciences, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan 3 Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, Kurokawa, Imizu, Toyama 939-0398, Japan 4 International Institute of Active Vitamin D Analogs, 35-6, Sankeidai, Mishima, Shizuoka 411-0017, Japan 5 Food and Nutrition Laboratory, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan 6 Laboratory of Organic Synthesis and Medicinal Chemistry, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan ¶ These authors contributed equally to this work. * Corresponding authors: Yoshihisa Hirota Tel.: +81-48-7201-6037; Fax: +81-48-7201-6011; E-mail: hirotay@ shibaura-it.ac.jp Toshio Okano Tel.: (81) 78-441-7524; Fax: (81) 78-441-7524; E-mail: t-okano@kobepharma-u.ac.jp 1 bioRxiv preprint doi: https://doi.org/10.1101/349837; this version posted June 18, 2018.
    [Show full text]
  • A Clinical Update on Vitamin D Deficiency and Secondary
    References 1. Mehrotra R, Kermah D, Budoff M, et al. Hypovitaminosis D in chronic 17. Ennis JL, Worcester EM, Coe FL, Sprague SM. Current recommended 32. Thimachai P, Supasyndh O, Chaiprasert A, Satirapoj B. Efficacy of High 38. Kramer H, Berns JS, Choi MJ, et al. 25-Hydroxyvitamin D testing and kidney disease. Clin J Am Soc Nephrol. 2008;3:1144-1151. 25-hydroxyvitamin D targets for chronic kidney disease management vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin supplementation in CKD: an NKF-KDOQI controversies report. Am J may be too low. J Nephrol. 2016;29:63-70. D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD Kidney Dis. 2014;64:499-509. 2. Hollick MF. Vitamin D: importance in the prevention of cancers, type 1 with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial. diabetes, heart disease, and osteoporosis. Am J Clin Nutr 18. OPKO. OPKO diagnostics point-of-care system. Available at: http:// J Med Assoc Thai. 2015;98:643-648. 39. Jetter A, Egli A, Dawson-Hughes B, et al. Pharmacokinetics of oral 2004;79:362-371. www.opko.com/products/point-of-care-diagnostics/. Accessed vitamin D(3) and calcifediol. Bone. 2014;59:14-19. September 2 2015. 33. Kovesdy CP, Lu JL, Malakauskas SM, et al. Paricalcitol versus 3. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 40. Petkovich M, Melnick J, White J, et al. Modified-release oral calcifediol of vitamin D status and cancer incidence and mortality in men.
    [Show full text]
  • Toiminta Unita on Ulla La Mungukurti |
    TOIMINTAUNITA USON 20180071390A1ULLA LA MUNGUKURTI | ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0071390 A1 PATEL et al. (43 ) Pub . Date : Mar . 15 , 2018 ( 54 ) COMPOSITIONS OF PHARMACEUTICAL A61K 9 / 06 (2006 .01 ) ACTIVES CONTAINING DIETHYLENE A61K 9 /00 (2006 .01 ) GLYCOL MONOETHYL ETHER OR OTHER A61K 31 /573 ( 2006 .01 ) ALKYL DERIVATIVES A61K 31/ 565 ( 2006 .01 ) A61K 31/ 4439 ( 2006 . 01 ) ( 71 ) Applicant : THEMIS MEDICARE LIMITED , A61K 31 / 167 ( 2006 . 01 ) Mumbai (IN ) A61K 31 / 57 (2006 . 01) (52 ) U . S . CI. (72 ) Inventors : Dinesh Shantilal PATEL , Mumbai CPC .. .. .. A61K 47 / 10 ( 2013 . 01 ) ; A61K 9 /4858 ( IN ) ; Sachin Dinesh PATEL , Mumbai ( 2013 .01 ) ; A61K 9 /08 ( 2013 .01 ) ; A61K 9 / 06 ( IN ) ; Shashikant Prabhudas ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 .01 ) ; A61K KURANI, Mumbai ( IN ) ; Madhavlal 31/ 573 ( 2013 .01 ) ; A61K 31 /57 ( 2013 .01 ) ; Govindlal PATEL , Mumbai ( IN ) A61K 31/ 565 ( 2013 .01 ) ; A61K 31 /4439 (73 ) Assignee : THEMIS MEDICARE LIMITED , ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Mumbai (IN ) 9 /0048 ( 2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ( 57 ) ABSTRACT (21 ) Appl. No .: 15 / 801, 390 The present invention relates to pharmaceutical composi tions of various pharmaceutical actives, especially lyophilic ( 22 ) Filed : Nov . 2 , 2017 and hydrophilic actives containing Diethylene glycol mono ethyl ether or other alkyl derivatives thereof as a primary Related U . S . Application Data vehicle and /or to pharmaceutical compositions utilizing (62 ) Division of application No. 14 /242 , 973 , filed on Apr. Diethylene glycol monoethyl ether or other alkyl derivatives 2 , 2014 , now Pat. No. 9 , 827 ,315 .
    [Show full text]